CCEA approves proposal of Mylan Illustrative image – not actual.

The Cabinet Committee on Economic Affairs (CCEA) has approved the proposal of US-based pharmaceutical firm, Mylan Inc, to invest in India's drug company.


The company has proposed to invest Rs 5,168 crore to acquire the Indian generic drugs company, Agila Specialties. The approval was given when an inter-ministerial group, headed by the Prime Minister, decided to approve all pending proposals based on the existing FDI policy.


Last month, FIPB had put Mylan's proposal on hold, citing opposition from the Department of Industrial Policy & Promotion (DIPP). The DIPP was of the view that flow of pharmaceutical FDI could seriously affect the country's capacity to produce low cost generic drugs.


 

← All latest storiesBack to top →